Etiopathogenetic structure of hypochromic anemias, differential diagnosis, approaches to the treatment

  • O.M. Bereziuk
Keywords: anemia, hypoxia, iron deficiency anemia, functional deficiency of iron, anemia of chronic disease, anemia of cancer.


The issue of differential diagnosis of hypochromic microcytic anemias has been discovered in the article. This is a heterogeneous group of anemias, which includes iron deficiency, iron redistributive (anemia of chronic disease, anemia of cancer) and sideroblastic anemia. The main reasons for the development of these anemias are considered. Features of complete blood count, cytological examination of bone marrow, iron metabolism indices, which allow identifying the type of anemia, are investigated. The effectiveness of correction of hypochromic anemias with different mechanism of development using the oral, parenteral iron preparations, erythropoietin and erythrocyte transfusions is estimated.


1. Schapkaitz, E., Buldeo, S. & Mahlangu, J. N. (2015). Diagnosis of iron deficiency anaemia in hospital patients: Use of the reticulocyte haemoglobin content to differentiate iron deficiency anaemia from anaemia of chronic disease. S. Afr. Med. J., 106 (1), 53–4.

2. Chrobák, L. (2001). Microcytic and hypochromic anemias. Vnitr. Lek., 47(3), 166–74.

3. Jimenez, K. & Lang, M. (2016). Diagnostic approach to iron deficiency anemia. Wien Med. Wochenschr., 166(13–14), 402–410.

4. Cullis, J. O. (2011). Diagnosis and management of anaemia of chronic disease: current status. Br. J. Haematol., 154(3), 289–300.

5. Link, H., Schiefke, I., Balck, K. & Doehner, W. (2015). Diagnostic and treatment principles of iron deficiency anaemia. MMW Fortschr. Med., 157 (18), 56–8.

6. Vyoral, D. & Jiri Petrak (2016) Therapeutic potential of hepcidin — the master regulator of iron metabolism. Pharmacol. Res., 115, 242–254.

7. Lee, P., Peng, H., Gelbart, T., Wang, L. & Beutler, E. (2005). Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc. Natl. Acad. Sci. USA, 102(6), 1906–1910.

8. Song, S. N., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T. & Yoshizaki, K. (2010). Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood, 116(18), 3627–3634.

9. Demirag, M. D., Haznedaroglu, S., Sancak, B. & Nangia, A. (2009). Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern. Med., 48(6), 421–426.

10. Gulen, H., Hanimeli, O., Karaca, O. & Taneli, F. (2012). α-Thalassemia frequency and mutations in children with hypochromic microcytic anemias and relation with β-thalassemia, iron deficiency anemia. Pediatr. Hematol. Oncol., 29(3), 241–6.

11. Brasse-Lagnel, C., Karim, Z., Letteron, P., Bekri, S., Bado, A. & Beaumont, C. (2011). Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology, 140 (4), 1261–1271.

12. Dahlerup J. F., Eivindson, M., Jacobsen, B. A., Jensen, N. M., Jørgensen, S. P., Laursen, S. B. … Nathan, T. (2015). Diagnosis and treatment of unexplained anemia with iron deficiency without overt bleeding. Dan. Med. J., 62 (4), C5072.

13. Hershko, C. & Skikne, B. (2009). Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis. Semin Hematol., 46 (4), 339–50.

14. Kellner, S. V., Kellner, Á., Haragh, A., Dombi, P., Karádi, É., Rajnics, P. … Egyed, M. (2016). Low mean cell hemoglobin is a reliable marker for iron deficiency screening. Orv. Hetil., 157 (1), 35–8.

15. Warsch, S. & Byrnes, J. (2013). Emerging causes of iron deficiency anemia refractory to oral iron supplementation. World J. Gastrointest. Pharmacol. Ther., 4 (3), 49–53.

16. Suzuki, M., Nakagawa, M., Shimizu, Y., Suemura, M. & Sato, B. (2005). Therapy-resistant microcytic hypochromic anemia from malabsorption-related vitamin B6 deficiency after a gastrointestinal operation. Rinsho Ketsueki., 46 (9), 1044–8.

17. Jimenez, K., Kulnigg-Dabsch, S. & Gasche, C. (2015). Management of Iron Deficiency Anemia. Gastroenterol. Hepatol. (N Y)., 11 (4), 241–50.

18. Sobrado, C. W., Cançado, R. D., Sobrado, L. F., Frugis, M. O. & Sobrado, M. F. (2015). Treatment of anemia and improvement of quality of life among patients with crohn's disease: experience using ferric carboxymaltose. Arq. Gastroenterol., 52 (4), 255–9.

19. Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Tsantes, A., Peyrin-Biroulet, L. & Danese, S. (2016). Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 95 (2), e2308.

20. Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U. & Gafter-Gvili, A. (2016). Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am. J. Kidney Dis., 68 (5), 677–690.

21. Massey, A. C. (1992). Microcytic anemia. Differential diagnosis and management of iron deficiency anemia. Med. Clin. North Am., 76 (3), 549–66.

22. Singh, A.K., Szczech, L., Tang, K. L. Barnhart, H., Sapp, S., Wolfson, M. & Reddan, D. (2006). Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med., 355 (20), 2085–2098.

23. Martí-Carvajal, A. J., Agreda-Pérez, L. H., Solà, I. & Simancas-Racines, D. (2013). Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst. Rev., 28 (2), CD000332.
How to Cite
Bereziuk, O. (2017). Etiopathogenetic structure of hypochromic anemias, differential diagnosis, approaches to the treatment. Reports of Vinnytsia National Medical University, 21(2), 419-424. Retrieved from